COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Novel prodrug platform enables drug delivery to lymphatic system

Researchers at the NCL have developed a nanotechnology platform which targets the lymphatic system via scavenger receptor A1 (SR-A1), a cell surface receptor highly expressed on cells lining the vasculature and myeloid cells within lymph nodes. By targeting the lymphatics, this poly(L-lysine succinylated) (PLS) polymer could provide new treatment options for a variety of diseases including cancer, which uses the lymphatic system to metastasize, HIV, whereby latent infection resides in the lymph nodes, and other applications such as vaccine delivery, immunomodulation and lymphatic imaging. Read more about the concept on the Frederck National Lab's website: https://frederick.cancer.gov/news/novel-prodrug-platform-enables-drug-de...

In collaboration with Jacob Estes, Ph.D., chief of the Division of Pathobiology & Immunology in the Oregon National Primate Research Center and Angela Kashuba, Ph.D., director of the Clinical Pharmacology and Analytical Chemistry Core in the UNC Center for AIDS Research, the team has developed an emtricitabine prodrug using the PLS technology, a reverse trasciptase inhibitor of HIV. In vitro and in vivo studies showed controlled release of the drug, conversion to the active metabolite, and an order of magnitude increased drug concentration in lymphatic tissue as compared to the free emtricitabine control. You can read the full details of these studies, recently published in Molecular Pharmaceutics, https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.0c00562. 

If you are interested in learning more about the PLS prodrug technology and/or discussing potential collaboration opportunities, please contact Dr. Stephan Stern, sternstephan@mail.nih.gov